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Abstract 
Rationale 
Central modulation of serotonin and dopamine underlies efficacy for a variety of psychiatric 
therapeutics. ITI-007 is an investigational new drug in development for treatment of 
schizophrenia, mood disorders, and other neuropsychiatric disorders. 
Objectives 
The purpose of this study was to determine brain occupancy of ITI-007 at serotonin 5-HT2A 
receptors, dopamine D2 receptors, and serotonin transporters using positron emission 
tomography (PET) in 16 healthy volunteers. 
Methods 
Carbon-11-MDL100907, carbon-11-raclopride, and carbon-11-3-amino-4-(2-
dimethylaminomethyl-phenylsulfanyl)-benzonitrile) (carbon-11-DASB) were used as the 
radiotracers for imaging 5-HT2A receptors, D2 receptors, and serotonin transporters, 
respectively. Brain regions of interest were outlined using magnetic resonance tomography 
(MRT) with cerebellum as the reference region. Binding potentials were estimated by fitting 
a simplified reference tissue model to the measured tissue-time activity curves. Target 
occupancy was expressed as percent change in the binding potentials before and after ITI-007 
administration. 
Results 
Oral ITI-007 (10–40 mg) was safe and well tolerated. ITI-007 rapidly entered the brain with 
long-lasting and dose-related occupancy. ITI-007 (10 mg) demonstrated high occupancy 
(>80 %) of cortical 5-HT2A receptors and low occupancy of striatal D2 receptors (~12 %). D2 
receptor occupancy increased with dose and significantly correlated with plasma 
concentrations (r 
2 = 0.68, p = 0.002). ITI-007 (40 mg) resulted in peak occupancy up to 39 % 
of striatal D2 receptors and 33 % of striatal serotonin transporters. 
Conclusions 
The results provide evidence for a central mechanism of action via dopaminergic and 
serotonergic pathways for ITI-007 in living human brain and valuable information to aid dose 
selection for future clinical trials. 
Keywords 
PET Antidepressant Antipsychotic Brain imaging Neuroimaging Dopamine receptor 
Serotonin receptor Human  
  
Introduction 
Modulation of serotonergic and dopaminergic neurotransmission in the central nervous 
system has proven to be an effective means of treating a variety of psychiatric and 
neurological disorders. Dopamine D2 receptor blockade, for example, is thought to mediate 
the ability of antipsychotic drugs to control positive symptoms (e.g., hallucinations and 
delusions) in patients with schizophrenia (Snyder 1976) whereas serotonin reuptake 
inhibition is thought to mediate antidepressant efficacy (Benfield et al. 1986; Benfield and 
Ward 1986). The possibility that antagonism of 5-HT2A receptors may act synergistically 
with antagonism of dopamine receptors to control psychotic behavior emerged with the 
introduction of clozapine. At therapeutic doses in patients with schizophrenia, clozapine 
exhibits mean dopamine D2 receptor occupancy (RO) of approximately 45 %, whereas the 5-
HT2A RO is approximately 90 % (Nordstrom et al. 1995). Many other atypical antipsychotic 
drugs have less selectivity for 5-HT2A receptors relative to dopamine receptors and only 
achieve high 5-HT2A RO at doses that also demonstrate high (>50 %) striatal D2 RO. For 
example, risperidone shows no or little separation between 5-HT2A and D2 RO, depending on 
the dose, with ≥78 % occupancy of 5-HT2A receptors and ≥75 % occupancy of D2 receptors at 
a 6 mg/day dose and approximately 83 % 5-HT2A RO and 72 % D2 RO at a dose of 3 mg/day 
(Farde et al. 1995; Nyberg et al. 1999). Olanzapine also shows little separation between 5-
HT2A RO (68–78 %) and striatal D2 RO (85–93 %; Kessler et al. 2005). These atypical 
antipsychotic drugs with relatively high striatial D2 RO elevate prolactin levels (Bushe et al. 
2008) and can induce extrapyramidal motor side effects (extrapyramidal symptoms (EPS)) at 
therapeutic doses (Rummel-Kluge et al. 2012). Importantly, selective 5-HT2A receptor 
antagonism has been shown to enhance D2-receptor-antagonist-mediated antipsychotic 
efficacy while reducing motor side effects and hyperprolactinemia in animal models (Gardell 
et al. 2007; Wadenberg et al. 1996). Moreover, antidepressant efficacy corresponding to 
occupancy of serotonin transporters (Meyer et al. 2004b; Meyer 2007) can be enhanced by 5-
HT2A receptor antagonism with reduced sexual side effects (Aizenberg et al. 1997; Marek et 
al. 2005; Pullar et al. 2000). A medication that combines potent 5-HT2A receptor antagonism 
with optimal dopamine D2 receptor modulation and optimal serotonin reuptake inhibition, 
never before achieved to our knowledge, may present an ideal balance of serotonergic and 
dopaminergic neurotransmission for the treatment of psychosis and mood disorders. By 
definition, this ideal balance would provide for robust antipsychotic and antidepressant 
efficacy mediated by D2 receptors and serotonin transporters, respectively, with minimal side 
effects associated with engagement of these targets. 
ITI-007 [4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-
pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluoro-phenyl)-butan-1-one 4-
methylbenzenesulfonate] represents a novel small-molecule therapeutic agent designed to act 
synergistically through serotonergic, dopaminergic, and glutamatergic pathways (Li et al. 
2014; Snyder et al. 2015). Specifically, ITI-007 combines potent 5-HT2A receptor antagonism 
with regionally specific modulation of dopaminergic intra-cellular phosphoprotein pathways 
and with serotonin reuptake inhibition. ITI-007 exhibits K i s of 0.54 nM at 5-HT2A receptors, 
32 nM at D2 receptors, and 61 nM at serotonin transporters (Li et al. 2014). ITI-007 has dual 
actions at dopamine D2 receptors in vivo, acting as a post-synaptic D2 receptor antagonist and 
as a pre-synaptic partial agonist at D2 receptors with mesolimbic/mesocortical selectivity 
(Snyder et al. 2015). ITI-007 also exhibits affinity for D1 receptors (K i  = 52 nM; Li et al. 
2014) and indirectly modulates glutamatergic activity in dopamine-rich mesolimbic brain 
regions by increasing the phosphorylation of the GluN2B subunit of N-methyl-d-aspartate 
(NMDA) channels (Snyder et al. 2015). In total, ITI-007 has a unique pharmacological 
profile useful for the treatment of schizophrenia and related psychoses as well as mood 
disorders. 
The in vitro profile of ITI-007 suggests that 5-HT2A receptors could be fully saturated before 
significant dopamine D2 RO is achieved. This is not possible with other antipsychotics 
wherein significant dopamine D2 RO and/or other potent receptor interactions are seen even 
at modest levels of 5-HT2A RO. With ITI-007, full occupancy of 5-HT2A RO is achieved at 
low doses, and then, the dose increased to bring in just enough dopamine receptor modulation 
and/or serotonin reuptake inhibition. This would allow optimal efficacy to be achieved 
without incurring unwanted side effects. Such a profile is not achieved even by the dopamine 
D2 receptor partial agonist which requires very high levels of D2 RO for antipsychotic 
efficacy (Yokoi et al. 2002); aripiprazole is a partial agonist both pre- and post-synaptically 
and has a higher affinity for D2 over 5-HT2A receptors, in contrast to the pre-synaptic partial 
agonism and post-synaptic antagonism at D2 receptors by ITI-007 and potent 5-HT2A receptor 
antagonism. Moreover, ITI-007 has minimal interaction with histamine, serotonin 5-HT2C, 
and muscarinic acetylcholine receptors that translate to a lack of sedation, metabolic 
disturbance, and cognitive dysfunction. 
The present study sought to determine if the unique in vitro receptor interaction profile of 
ITI-007 translated to a unique RO profile in the brain of healthy volunteers using positron 
emission tomography (PET) with appropriate ligands for labeling 5-HT2A receptors, D2 
receptors, and serotonin transporters. The relationship between ITI-007 dose and receptor 
occupancies as well as the relationship between ITI-007 plasma concentrations and receptor 
occupancies was also investigated. Safety and tolerability of ITI-007 after a single 
administration as an oral dose solution were evaluated. 
Subjects and methods 
Participants and ethical approval 
Sixteen healthy male subjects between the ages of 18 and 45 years old were recruited for the 
study. Subjects had to have a body mass index (BMI) of 19–30 kg/m2 with a minimum 
weight of 60 kg at screening. Subjects were excluded if they had any current or history of 
significant medical issue (e.g., organ abnormality or disease; renal, hepatic, gastrointestinal, 
cardiovascular, or hematological disease; neurological condition; psychiatric illness; alcohol 
and/or drug abuse). 
This study was conducted jointly at the Johns Hopkins University (JHU) School of 
Medicine/Johns Hopkins Hospital (JHH) and PAREXEL Early Phase Clinical Unit (EPCU; 
Baltimore, MD) and was approved by Institutional Review Boards for each institution (JHU 
School of Medicine: Office of Human Subjects Research, Baltimore, MD, USA and 
Chesapeake Research Review, Inc., Columbia, MD, USA) in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki. 
Study design 
This study was conducted as an open-label study. After providing written informed consent, 
subjects underwent a screening visit to determine eligibility within 28 days of the baseline 
PET scan. Subjects were admitted to the PAREXEL EPCU for the collection of baseline 
safety assessments and overnight housing. The following day, subjects were transported to 
JHH/JHU PET center. Test drug administration took place on study day 1 at JHU followed by 
PET scan(s), safety assessments, and blood collections for pharmacokinetic determinations 
for approximately 8 h post-dose. Subjects were discharged after the last assessment on study 
day 1 and returned to PAREXEL EPCU for a safety follow-up visit on study days 5 to 7. 
ITI-007 was administered at JHH/JHU as a single oral dose using an oral solution 
reconstituted from drug powder in degassed Sprite Zero® within 24 h before administration. 
Subjects received one baseline PET scan and up to three post-dose scans, as illustrated in 
Fig. 1. PET scans to image D2 receptors were conducted at various time points in groups 
receiving 10 mg (N = 2), 20 mg (N = 4), 30 mg (N = 4), or 40 mg (N = 2) ITI-007. Occupancy 
of serotonin 5-HT2A receptors at 10 mg ITI-007 (N = 2) and serotonin transporters at 40 mg 
ITI-007 (N = 2) was each determined in separate groups only at the time of peak brain 
occupancy (~30–120 min post-dose). 
 
Fig. 1 Timeline of scans relative to dose administration 
Radiotracers and positron emission tomography 
Carbon-11 radiolabeled compounds were manufactured at Johns Hopkins Hospital Nuclear 
Medicine Radiochemistry Facility according to the center’s standard operating procedures 
and in compliance with US Pharmacopoeia (USP) <823>, “Radiopharmaceuticals for 
positron emission tomography: compounding.” Each subject received a new batch of 
radiotracer manufactured and administered just before each PET scan. 
Carbon-11-raclopride ([
11
C]-RAC) was used for imaging D2 dopamine receptors (Ribeiro et 
al. 2005; Schlaepfer et al. 1997; Slifstein et al. 2006). Carbon-11-3-amino-4-(2-
dimethylaminomethyl-phenylsulfanyl)-benzonitrile) ([
11
C]-DASB) (Mathis et al. 2003; 
Wilson et al. 2002) was used to measure serotonin transporter binding (Frankle et al. 2005; 
Guttman et al. 2007; McCann et al. 2008; Meyer et al. 2004a; Reimold et al. 2008). Carbon-
11-MDL100907 ([
11
C]-MDL) was used for imaging 5-HT2A receptors (Bhagwagar et al. 
2006; de Paulis 2001; Hilton et al. 2000; Hinz et al. 2007; Hirani et al. 2003). The injected 
activity of radioisotopes administered in this study was approximately 20 mCi, and the 
radiation exposure was approximately 0.6- to 0.7-rem effective dose equivalent for each PET 
scan. A maximum of four PET scans was performed on each participant; thus, the total 
cumulative exposure during this study was less than 3.0-rem effective dose equivalent. The 
radiotracer was administered, followed by a 90-min dynamic PET scan. 
PET images were acquired on a high-resolution research tomograph (HRRT). The 
reconstructed dynamic PET images were attenuation- and decay-corrected and expressed in 
units of concentration (μCi/mmol). In addition to the PET scan, each participant had a 
volumetric magnetic resonance imaging (MRI) scan for co-registration with the PET data to 
enhance anatomical definitions. The MRI data were acquired using a spoiled gradient 
recalled acquisition in the steady state (GRASS) (SPGR) sequence on a GE 1.5 T Signa 
Camera. To minimize movement during the MRI and PET scans, each participant was fitted 
with a thermoplastic facemask that was secured to the scanner bed during imaging. 
Subjects receiving [
11
C]-MDL or [
11
C]-DASB had blood samples drawn through an arterial 
line for determination of total and metabolite-associated radioactivity in plasma. Before start 
of a [
11
C]-MDL or [
11
C]-DASB PET scan, subject had a venous catheter inserted into one of 
his arms to administer the radiotracer, and a second venous catheter or radial arterial line was 
inserted for blood sampling. Radioactivity and radiotracer metabolite concentrations in 
plasma were measured within the JHU facility using a validated high-performance liquid 
chromatography (HPLC) method/appropriate radioactive analytical method (Hilton et al. 
2000). These data were used for construction of a metabolite-corrected plasma input function 
to calculate specific uptake of the radiotracer in different regions of the brain. 
Pharmacokinetics of ITI-007 
Blood samples (approximately 7 mL) for ITI-007 (and two metabolites) used for drug 
concentration determination were collected into polypropylene tubes containing sodium 
heparin immediately pre-dose (0 h) and at approximately 1, 3.5, and 8 h post-dose. 
Immediately after blood collection, the tube was inverted gently and placed on ice. Samples 
were centrifuged at 4 °C for 10 min at 2500 × g within 15 min of collection and then stored 
frozen at approximately −80 °C until analysis. Plasma samples were analyzed for ITI-007 and 
metabolite concentrations using validated HPLC/tandem mass spectrometry (HPLC/MS/MS) 
bioanalytical assays. The assay was validated at a level of detection of 0.05 to 50 ng/mL for 
the parent and 0.2 to 100 ng/mL for the metabolites. 
Safety 
Safety was monitored during the study by the performance of the following procedures and 
assessments at regular intervals: vital signs (three-positional blood pressure and heart rate, 
oral body temperature, and respiratory rate), 12-lead electrocardiograms (ECGs), clinical 
laboratory testing (hematology, clinical chemistry, and urinalysis), adverse event (AE) 
assessments, and physical examinations. 
Data analysis 
Regions of interest (ROIs) were drawn for PET data: caudate and putamen for D2 RO; 
midbrain, thalamus, caudate, putamen, and pons for serotonin transporters; frontal cortex for 
5-HT2A RO; and cerebellum used as a reference region. Target occupancies of ITI-007 were 
calculated as the percent change of non-displaceable binding potential (BPND) from baseline: 
Occupancy (%) = 100 × (BPND(baseline) − BPND(blocking))/ BPND(baseline). Specific 
binding (i.e., BPND) in all ROIs was obtained by using simplified reference tissue modeling 
(SRTM) for [
11
C]-RAC only. Parametric maps of the BPND were created from the PET ROI 
data as follows: For [
11
C]-RAC, ROIs were defined on co-registered MRI images and then 
applied to dynamic PET images to obtain time-activity curves for use in kinetic modeling, in 
this case, using SRTM. Then, using the linear regression with spatial constraint method 
(Zhou et al. 2003), parametric maps of binding potential were generated. ROIs were then 
applied to the parametric maps to obtain mean regional BPNDs. For [
11
C]-DASB and [
11
C]-
MDL, distribution volume (DV) maps were generated using multigraphical analysis using 
plasma input (Zhou et al. 2010). BPND images were created from the DV maps using 
DV/DVcerebellum] − 1 [, where cerebellum was the reference region. 
RO was calculated as the percent change in BPND in the blocking vs. baseline scans. Plasma 
concentrations of the blocking drug and RO were fitted to a concentration-occupancy model, 
to estimate a half maximal effective concentration (EC50). Individual subject ITI-007 and 
metabolite plasma concentration data were correlated with the individual levels of D2 RO. 
Results 
Enrollment 
Sixteen (16) subjects were enrolled; all completed the study and were included in the 
analyses. Participants had a mean age of 30.7 years (±6.4 standard deviation) with an average 
BMI of 24.6 (±3.0). Ten subjects (62.5 %) were Black/African American, and six (37.5 %) 
were Caucasian. Of the 16 subjects enrolled, two (12.5 %) were of Hispanic/Latino ethnicity. 
Positron emission tomography 
The main outcome variables from the PET data were non-displaceable binding potential 
(BPND), and RO. Baseline BPND ranged from 1.5 to 3.6 for [
11
C]-RAC, from 1.7 to 5.8 for 
[
11
C]-DASB, and from 1.6 to 2.9 for [
11
C]-MDL. Estimates of BPND derived from ROIs 
directly by SRTM correlated closely with estimates of BPND derived from the parametric 
maps, with less than a 5 % difference in BPND estimates between the two methods for all 
subjects. 
Table 1 summarizes the mean striatal D2 RO, average of the putamen and caudate 
occupancies for each subject, and averaged across subjects by dose and time. Taken together, 
these data illustrate that ITI-007 rapidly enters the brain and occupies striatal D2 receptors, 
with peak RO within 30 min to 1 h after oral administration. Striatal D2 RO increased with 
higher doses of ITI-007. Striatal D2 RO after ITI-007 administration was measureable in 
scans starting as late as 7.5 h after administration of 40 mg ITI-007. 
Table 1 Striatal D2 receptor occupancy of ITI-007 by dose and time 
  Mean (individual values) striatal D2 % receptor occupancy 
ITI-007 dose 
(mg) 
30 min–1 h post-dose 2–3.5 h post-dose 5–7.5 h post-dose 
10 11.56 % (6.36, 16.75)     
20 19.03 % (18.46, 19.60) 8.19 % (8.03, 8.35)   
30 
26.53 % (17.82, 30.18, 
31.58) 
18.17 % (13.01, 18.33, 
23.17) 
12.05 % (6.16, 7.27, 
22.27) 
40 28.76 % (18.70, 38.81) 23.25 % (19.30, 27.19) 13.83 % (10.17, 17.48) 
At a dose of 10 mg administered approximately 30 min before the PET scan, ITI-007 
demonstrated high occupancy (>80 %) of cortical 5-HT2A receptors (Table 2). At a dose of 
40 mg administered approximately 30 min before the PET scan, ITI-007 demonstrated 
occupancy of striatal serotonin transporters (8–33 %; Table 3) in the same range as its D2 RO 
(19–39 %). 
Table 2 Cortical 5-HT2A receptor occupancy by 10 mg ITI-007 
Mean (Individual Values) 5-HT2A % Receptor Occupancy 
Pre-frontal 
cortex 
Orbital 
cortex 
Temporal 
cortex 
Occipital 
cortex 
Superfrontal 
cortex 
Parietal 
cortex 
Cingulate 
cortex 
87.7 % 
(83.8, 
91.6) 
87.3 % 
(85.5, 
89.2) 
83.9 % 
(81.1, 86.7) 
83.3 % 
(78.4, 88.3) 
87.4 % (83.4, 
91.4) 
84.7 % 
(78.9, 90.5) 
81.0 % 
(78.9, 83.0) 
 
Table 3 Serotonin transporter occupancy by 40 mg ITI-007 
Mean (individual values) serotonin transporter % occupancy 
Caudate Putamen Thalamus Pons Midbrain 
20.7 % (8.3, 
33.1) 
24.1 % (19.0, 
29.2) 
21.1 % (9.9, 
32.4) 
19.3 % (10.8, 
27.7) 
27.5 % (11.5, 
43.6) 
Pharmacokinetic-pharmacodynamic relationships 
Plasma concentrations of ITI-007 (parent and two metabolites) were measured. Striatal D2 
RO was significantly correlated with ITI-007 parent plasma concentrations (r 
2 = 0.68, 
p = 0.002; Fig. 2a) and with ITI-007 total exposure (r 2 = 0.75, p = 0.0005; Fig. 2b). 
 
Fig. 2 Percent striatal D2 receptor occupancy as a function of a ITI-007 parent 
plasma level (ng/mL) or b total exposure (parent+metabolites (ng/mL) 
When the D2 RO data were plotted against plasma concentration of ITI-007 (parent) and 
fitted to a concentration-occupancy model (% Occupancy = 100 × [Conc / (EC50 + Conc)]), 
the predicted EC50 was estimated to be 24 ng/mL of parent if B max was assumed to be 100 
and, as a sensitivity analysis, was determined to be 26 ng/mL of parent if B max was assumed 
to be 90 (Fig. 3). 
 
Fig. 3 Percent striatal D2 receptor occupancy projections 
There was little variability with regard to 5-HT2A RO between the two subjects tested, and 
these two subjects showed similar ITI-007 plasma levels. Average occupancy for the two 
subjects evaluated was 88 % of 5-HT2A receptors in the pre-frontal cortex with a range of 
84 % minimum (corresponding to 0.72 ng/mL of parent and 2.55 ng/mL of parent plus 
metabolites) and 92 % maximum or peak (corresponding to 2.16 ng/mL of parent and 
5.33 ng/mL of parent plus metabolites). Moreover, these plasma levels were similar to those 
achieved at the 10-mg ITI-007 dose level in the subjects from the D2 RO portion of the 
experiment. 
With regard to serotonin transporter occupancy, one subject with 15.6 ng/mL ITI-007 
(parent) and 35.1 ng/mL total (parent + metabolites) concentrations showed approximately 
31 % striatal serotonin transporter occupancy, whereas the other subject with 18.3 ng/mL ITI-
007 (parent) and 61.7 ng/mL total (parent + metabolites) concentrations showed only 14 % 
serotonin reuptake inhibition. However, this range of plasma levels observed at 40 mg ITI-
007 in the serotonin transporter occupancy subjects was similar to the range measured at the 
same dose in the D2 RO subjects. 
Safety 
Oral administration of 10–40 mg ITI-007 was safe and well tolerated in healthy volunteers. 
There were no dose-related or serious AEs. There were no clinically significant findings in 
safety data, including physical exams and clinical laboratory tests. There were no clinically 
relevant differences identified in mean observed vital sign data within each ITI-007 dose 
group over time or between doses, and there were no clinically relevant mean changes from 
baseline. There were no findings on ECG measures considered to be clinically significant. 
Mean values of the corrected QT interval using the formulae of Bazett (QTcB) and Fridericia 
(QTcF) were <430 ms, and QT values were <500 ms at all time points throughout the study 
for all dose groups. 
Discussion 
ITI-007 rapidly penetrated into the brain with extended, dose-related, and plasma-
concentration-related striatal D2 RO in healthy volunteers. A low dose of 10 mg ITI-007 
essentially fully saturated cortical 5-HT2A receptors with lesser striatal D2 RO, consistent 
with the 5-HT2A receptor selectivity of ITI-007 in vitro and in animal models (Snyder et al. 
2015). A higher dose of ITI-007 (40 mg) produced similar striatal D2 RO and striatal 
serotonin transporter occupancy. Taken together, these data demonstrate that low doses of 
ITI-007 are predominantly serotonin 5-HT2A receptor selective, while higher doses also 
engage dopamine D2 receptors and serotonin transporters. 
Serotonin 5-HT2A receptor occupancy 
ITI-007 demonstrated relatively high selectivity for serotonin 5-HT2A receptors at low doses. 
The pattern of high RO of 5-HT2A receptors at low doses and large separation between other 
pharmacological activities were predicted based on in vivo animal studies. At low doses 
(0.2 mg/kg, p.o.) in rodents, ITI-007 selectively inhibits brain 5-HT2A receptors and blocks 
quipazine-induced head twitches (Snyder et al. 2015). Serotonin 5-HT2A receptor antagonism 
has been strongly linked with sleep maintenance (Vanover and Davis 2010). 5-HT2A receptor 
binding may also influence impulsive aggression (Meyer et al. 2008; Rosell et al. 2010). 
Moreover, selective 5-HT2A receptor antagonists have been shown to enhance D2-receptor-
mediated antipsychotic-like efficacy in animal models (Gardell et al. 2007; Wadenberg et al. 
2001; Wadenberg et al. 2000; Wadenberg et al. 1996) without altering or even decreasing D2-
receptor-mediated extrapyramidal motor side effects and hyperprolactinemia (Gardell et al. 
2007; Wadenberg et al. 1996), likely due to a complex and regionally selective interaction 
between 5-HT2A and dopamine receptors in the brain (see review by Alex and Pehek 2007). 
Serotonin 5-HT2A receptor antagonism can also enhance serotonin-transporter-inhibition-
mediated antidepressant-like efficacy in animal models (Marek et al. 2005). Taken together, 
the data suggest a role for 5-HT2A RO in the treatment of a wide range of psychiatric 
disorders. 
Dopamine D2 receptor occupancy 
Early data suggested that greater than 60 % striatal D2 RO was required for antipsychotic 
clinical response and greater than 80 % striatal D2 RO was associated with extrapyramidal 
side effects (Farde et al. 1992; Nordstrom et al. 1993), and this D2 RO relationship appeared 
to hold true for classical antipsychotics (Kapur et al. 2000). However, clozapine, with 
relatively more potent 5-HT2A receptor antagonism than earlier antipsychotic drugs, was 
noted to exhibit antipsychotic efficacy at lower levels of D2 RO (Farde et al. 1992). 
Subsequent studies confirmed that both clozapine and quetiapine are exceptions to the “rule” 
and exhibit antipsychotic efficacy with less than 50 % striatal D2 RO (Kessler et al. 2006). 
Similarly, ITI-007’s high 5-HT2A RO and relative selectivity for 5-HT2A over D2 receptors 
suggests that ITI-007 will demonstrate antipsychotic efficacy at relatively low levels of 
striatal D2 RO. In contrast, not all atypical antipsychotics achieve efficacy at low levels D2 
RO. Lurasidone’s antipsychotic efficacy is associated with >60 % striatal D2 RO (Wong et al. 
2013), and aripiprazole’s antipsychotic efficacy is associated with greater than 90 % D2 RO 
(Yokoi et al. 2002). Aripiprazole may achieve antipsychotic efficacy at only relatively higher 
D2 RO compared to most other antipsychotics due to its partial agonism at D2 receptors. 
Partial agonism at D2 receptors may be associated with lower levels of some forms of 
extrapyramidal side effects, such as parkinsonism, despite high levels of D2 occupancy 
(Grunder et al. 2003), but may be associated with relatively high rates of akathisia (Mamo et 
al. 2007; Poyurovsky et al. 2008). Interestingly, 5-HT2A receptor antagonism has been 
suggested to attenuate D2-receptor-mediated akathisia and a high 5-HT2A/D2 occupancy ratio, 
which aripiprazole lacks, has been suggested as “essential” to prevent antipsychotic-induced 
akathisia (Poyurovsky et al. 2008). 
Clozapine and quetiapine, two other antipsychotic drugs with higher affinity for 5-HT2A 
receptors than for D2 receptors, exhibit higher levels of extrastriatal D2 RO than striatal D2 
RO using [18 F]-fallypride as the radiotracer (Grunder et al. 2006; Kessler et al. 2006; 
Vernaleken et al. 2010). This profile is thought to contribute to the lower incidence of 
extrapyramidal side effects with these drugs compared to other antipsychotics. The potent 
cortical 5-HT2A RO demonstrated in the present study suggests low liability of 
extrapyramidal side effects with ITI-007. Future investigation of extrastriatal D2 RO with 
ITI-007 would be of interest to see if the pattern of higher extrastriatal than striatal D2 RO 
holds true for ITI-007. In contrast to quetiapine and clozapine and other antipsychotics, ITI-
007 exhibits the additional occupancy of serotonin transporters in the same dose range as its 
striatal D2 RO. 
Serotonin transporter occupancy 
Serotonin transporter occupancy of about 80–90 % by selective serotonin reuptake inhibitors 
is associated with antidepressant efficacy (Meyer 2007; Meyer et al. 2004b). As mentioned 
above, serotonin 5-HT2A receptor antagonism can enhance serotonin-reuptake-inhibition-
mediated antidepressant-like efficacy in animal models (Marek et al. 2005). This suggests 
that in combination with 5-HT2A receptor antagonism, antidepressant efficacy can be 
achieved at lower levels of serotonin reuptake inhibition and/or for greater therapeutic 
efficacy (Marek et al. 2003). Moreover, combining atypical antipsychotic activity (i.e., 5-
HT2A and D2 receptor antagonism) with serotonin reuptake inhibition provides for synergistic 
activity than either mechanism alone (Reus et al. 2012; Tohen et al. 2010). Unique among 
antipsychotics, measurable serotonin transporter occupancy was found at doses of ITI-007 
that similarly occupy D2 receptors. These results suggest that ITI-007 combines antipsychotic 
and antidepressant mechanisms in a single compound. 
Limitations 
The estimated striatal D2 RO EC50 for ITI-007 of 24–26 ng/mL (parent) was based on the 
ascending portion of the curve without reaching full saturation of D2 receptors. Therefore, D2 
receptor occupancies above doses of 40 mg ITI-007 with associated parent plasma 
concentrations of 18 ng/mL had to be extrapolated. The raclopride radiotracer binds to D2 and 
D3 dopamine receptor subtypes, so displacement of raclopride by ITI-007 may be partially 
due to displacement at D3 receptors. However, this is unlikely because ITI-007 showed little 
or no affinity for dopamine D3 receptors in vitro as tested in a broad panel of receptors 
(Snyder et al. 2015). Additionally, the sample size of the study was small with two to four 
subjects per dose per radioligand which may have affected the accuracy of the projection of 
an EC50 value. However, the low dose range of 10–40 mg ITI-007 showed a predictable dose 
relationship with plasma concentrations highly correlated with striatal D2 RO and with good 
correspondence to in vitro receptor affinity (Li et al. 2014). 
Conclusions 
These data provide the first demonstration for a central mechanism of action via serotonergic 
and dopaminergic pathways for ITI-007 in living human brain. Moreover, these data in 
healthy volunteers correspond well to the preclinical data and provide further evidence for a 
separation between ITI-007’s 5-HT2A receptor antagonism and its other dopaminergic and 
serotonergic modulation (Table 4). This separation of pharmacological effects provides an 
opportunity to treat different symptoms and/or different neuropsychiatric disorders at 
different doses of ITI-007. The present data provide valuable information to aid dose 
selection for future efficacy clinical trials with ITI-007. 
Table 4 In vitro binding affinity and human receptor occupancy profiles of ITI-007 
and antipsychotic drugs 
In vitro binding affinity K i (nM) for 5-HT2A versus D2 receptors
a
  
  ITI-007 Clozapine Risperidone Olanzapine Aripiprazole 
5-HT2A  0.5 9.6 0.5 2.5 9 
D2  32 190 5.9 31 1.6 
Serotonin Transporters 62 >1000 >1000 >1000 240–405 
Selectivity for 5-HT2A versus D2 receptors in vitro 
  ITI-007 Clozapine Risperidone Olanzapine Aripiprazole 
Ratio D2/5-HT2A  60 20 12 12 0.18 
5-HT2A versus D2 receptor occupancy at efficacious antipsychotic dose
b
  
  ITI-007 Clozapine Risperidone Olanzapine Aripiprazole 
5-HT2A  Projected ≥90 % 90 % ≥78 % 68–78 % 54–60 % 
D2  Projected ≤50 % 45 % ≥72 % 85–93 % >90 % 
a
In vitro receptor binding affinities from Snyder et al. (2015) and derived from the NIMH 
Psychoactive Drug Screening Program (PDSP) Database (Roth et al. 2004) 
b
Receptor occupancy data using PET: ITI-007 data projected to the efficacious antipsychotic 
dose of 60 mg ITI-007 (Vanover et al. 2014) based on the present data determined at lower 
doses; clozapine data from Farde et al. (1992) and Kessler et al. (2006); risperidone data from 
Farde et al. (1995) and Nyberg et al. (1999); olanzapine data from Kessler et al. (2005); and 
aripiprazole data from Mamo et al. (2007) and Yokoi et al. (2002) 
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